SPERO THERAPEUTICS INC (SPRO)

US84833T1034 - Common Stock

1.47  -0.04 (-2.65%)

After market: 1.47 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SPERO THERAPEUTICS INC

NASDAQ:SPRO (2/22/2024, 6:12:10 PM)

After market: 1.47 0 (0%)

1.47

-0.04 (-2.65%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap77.91M
Shares
PE13.36
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SPRO Daily chart

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV)-administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections in the hospital setting.

Company Info

SPERO THERAPEUTICS INC

675 Massachusetts Ave Ste 14

Cambridge MASSACHUSETTS 02139

P: 18572421600

CEO: Ankit Mahadevia

Employees: 35

Website: https://sperotherapeutics.com/

SPRO News

News Image22 days ago - Spero Therapeutics, Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics Provides Corporate Update and 2024 Outlook

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

$95 million in development milestones payable over two years, as part of GSK license agreement...

News Image4 months ago - Bragar Eagel & Squire, P.C.SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
News Image4 months ago - Spero Therapeutics, Inc.Spero Therapeutics to Present at Upcoming November Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...

News Image4 months ago - Seeking AlphaSpero Therapeutics appoints Esther Rajavelu as CFO (NASDAQ:SPRO)

Spero Therapeutics appoints Esther Rajavelu as CFO and chief business officer, replacing interim CFO Stephen DiPalma.

SPRO Twits

Here you can normally see the latest stock twits on SPRO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example